Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586–97.
Hayes-Lattin B, Seipel TJ, Gatter K, Heinrich MC, Maziarz RT. Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation. Am J Hematol. 2004;75:142–45.
Kampouri E, Little JS, Crocchiolo R, Hill JA. Human herpesvirus-6, HHV-8 and parvovirus B19 after allogeneic hematopoietic cell transplant: the lesser-known viral complications. Curr Opin Infect Dis. 2024;37:245–53.
Russcher A, Verweij EJT, Maurice P, Jouannic J-M, Benachi A, Vivanti AJ, et al. Extreme upsurge of parvovirus B19 resulting in severe fetal morbidity and mortality. Lancet Infect Dis. 2024;24:e475–6.
Khamitova I, Lavrentyeva I, Averyanova M, Chukhlovin A, Zubarovskaya L, Afanasyev B. Parvovirus B19 incidence, specific antibody response, and delayed hematopoietic recovery after allogeneic hematopoietic stem cell transplantation. Cell Ther Transplant. 2018;7:36–43.
Katoh D, Ochi Y, Hiramoto N, Morita M, Yabushita T, Shimomura Y, et al. Parvovirus B19 infection in adult patients after allogeneic stem cell transplantation: our experience of five cases and literature review. Bone Marrow Transpl. 2020;55:653–56.
Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. 2006;43:40–8.
Mogensen TH, Skouboe MK, Mølle I. Successful use of interferon alfa-2a for persistent parvovirus B19 infection. Lancet Infect Dis. 2023;23:e160–5.
Adamson-Small LA, Ignatovich IV, Laemmerhirt MG, Hobbs JA. Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process. Virus Res. 2014;190:8–16.
Rattani N, Matheny C, Eckrich MJ, Madden LM, Quigg TC. Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation. Cancer Rep. 2022;5:e1403.
Wang J, Su M, Wei N, Yan H, Zhang J, Gong Y, et al. Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells. Blood. 2024;143:32–41.
Crawford LB, Hancock MH, Struthers HM, Streblow DN, Yurochko AD, Caposio P, et al. CD34(+) hematopoietic progenitor cell subsets exhibit differential ability to maintain human cytomegalovirus latency and persistence. J Virol. 2021;95:e02105-20.
Hirche C, Frenz T, Haas SF, Döring M, Borst K, Tegtmeyer PK, et al. Systemic virus infections differentially modulate cell cycle state and functionality of long-term hematopoietic stem cells in vivo. Cell Rep. 2017;19:2345–56.
Nasiri K, Mohammadzadehsaliani S, Kheradjoo H, Shabestari AM, Eshaghizadeh P, Pakmehr A, et al. Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects. Cell Commun Signal. 2023;21:103.
Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423:255–60.
Ganapathi KA, Townsley DM, Hsu AP, Arthur DC, Zerbe CS, Cuellar-Rodriguez J, et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. Blood. 2015;125:56–70.
Williams MJ, Wang X, Bastos HP, Grondys-Kotarba G, Wu Q, Jin S, et al. Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition. Blood Adv. 2025;9:291–309.
Ganaie SS, Zou W, Xu P, Deng X, Kleiboeker S, Qiu J. Phosphorylated STAT5 directly facilitates parvovirus B19 DNA replication in human erythroid progenitors through interaction with the MCM complex. PLoS Pathog. 2017;13:e1006370.
Johnson CS, Williams M, Sham K, Belluschi S, Ma W, Wang X, et al. Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle. Blood. 2024;144:729–41.
Morot J, Del Duca E, Chastagner M, Fernandes M, Estrada Y, Lefevre MA, et al. Hyperactivation of the JAK2/STAT5 signaling pathway and evaluation of baricitinib treatment among patients with eosinophilic cellulitis. JAMA Dermatol. 2023;159:820–29.
Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40:843–56.
Chen AY, Zhang EY, Guan W, Cheng F, Kleiboeker S, Yankee TM, et al. The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells. Blood. 2010;115:1070–80.
Ning K, Zou W, Xu P, Cheng F, Zhang EY, Zhang-Chen A, et al. Identification of AXL as a co-receptor for human parvovirus B19 infection of human erythroid progenitors. Sci Adv. 2023;9:eade0869.
Sammut R, Feghoul L, Xhaard A, Dhedin N, Robin M, Michonneau D, et al. Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study. Transpl Infect Dis. 2023;25:e14118.
Morita E, Sugamura K. Human parvovirus B19-induced cell cycle arrest and apoptosis. Springe Semin Immunopathol. 2002;24:187–199.
Raghuvanshi R, Bharate SB. Recent developments in the use of kinase inhibitors for management of viral infections. J Med Chem. 2022;65:893–921.
Read JA, Rouce RH, Mo F, Mamonkin M, King KY. Apoptosis of hematopoietic stem cells contributes to bone marrow suppression following chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29:165.e161–7.
Persaud SP, Cooper ML, Ritchey JK, Rettig MP, DiPersio JF. Antibody-drug conjugates targeting CD45 plus janus kinase (JAK) inhibitors as conditioning for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26:S150–1.
Thoms BL, Gosselin J, Libman B, Littenberg B, Budd R. Efficacy of combination therapy with the JAK inhibitor baricitinib in the treatment of COVID-19. SN Compr Clin Me. 2022;4:42.
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–1.
Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32:2483–94.
Zhao P, An ZY, Fu HX, Liu HX, Feng CJ, Huang QS, et al. Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: an open-label pilot study. Am J Hematol. 2024;99:1951–58.
Xu C, Prete M, Webb S, Jardine L, Stewart BJ, Hoo R, et al. Automatic cell-type harmonization and integration across Human Cell Atlas datasets. Cell. 2023;186:5876–5891.e5820.
Kang M, Armenteros JJA, Gulati GS, Gleyzer R, Avagyan S, Brown EL, et al. Mapping single-cell developmental potential in health and disease with interpretable deep learning. bioRxiv. 2024;2024.03.19.585637.
Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14:979–82.
Garcia-Alonso L, Holland CH, Ibrahim MM, Turei D, Saez-Rodriguez J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 2019;29:1363–75.
Villar J, Cros A, De Juan A, Alaoui L, Bonte P-E, Lau CM, et al. ETV3 and ETV6 enable monocyte differentiation into dendritic cells by repressing macrophage fate commitment. Nat Immunol. 2023;24:84–95.
Liu Z, Liu J, Zhang T, Li L, Zhang S, Jia H, et al. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. BMC Cancer. 2021;21:732.
